ACRP GCP Courses Recognized for Good Clinical Practice by TransCelerate Biopharma - Applied Clinical Trials


See our 2013 Buyers Guide Digital Edition.
ACRP GCP Courses Recognized for Good Clinical Practice by TransCelerate Biopharma

Source: Company News Release

The Association of Clinical Research Professionals (ACRP) is pleased to announce that TransCelerate Biopharma, Inc. now recognizes completion of any one of three ACRP professional development courses devoted to the international quality standard for Good Clinical Practice (GCP) as evidence of required GCP training for site-based researchers involved in clinical trials sponsored by TransCelerate member firms.

GCP, especially as interpreted in the International Conference on Harmonization (ICH) guidelines, encompasses an effort through quality assurance and inspections to enforce tighter guidelines on ethical aspects of human rights in clinical studies. The GCP-related courses highlighted by TransCelerate and already available in a self-paced, online format through ACRP (see include:

This announcement follows up on TransCelerate's decision in January to recognize certification through the Certified Clinical Research Coordinator (CCRC®) and Certified Physician Investigator (CPI®) programs of ACRP's affiliate, the Academy of Clinical Research Professionals, as evidence of GCP training (see

TransCelerate's membership of pharmaceutical and biotechnology companies with research and development (R&D) operations, including 17 major firms to date working together to create efficiencies within the clinical trials process, will save time and resources by not requiring CCRCs and CPIs involved in their trials or researchers that completed any of the three GCP related courses as listed above to complete redundant GCP training for each and every new study team they join. TransCelerate launched in 2012 to advance innovation in R&D, identify and solve common R&D challenges, and further improve patient safety with founding members AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer, Roche, and Sanofi.

"Being recognized by TransCelerate is a great achievement for ACRP and offers several advantages to our members, who now have more opportunity to focus on the actual conduct of clinical trials instead of having to use valuable time and resources sitting in redundant GCP training," says Esther Daemen, ACRP Director of Professional Development. "Through completion of ACRP's high-quality GCP courses, clinical trial stakeholders can be assured that researchers have the required knowledge to perform accordingly, making additional courses obsolete."


blog comments powered by Disqus



8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
View Results
Untitled Document
Source: Company News Release,
Click here